Will Complement Inhibition Be the New Target in Treating COVID-19–Related Systemic Thrombosis?

Abstract

HomeCirculationVol. 141, No. 22Will Complement Inhibition Be the New Target in Treating COVID-19–Related Systemic Thrombosis? Free AccessArticle CommentaryPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessArticle CommentaryPDF/EPUBWill Complement Inhibition Be the New Target in Treating COVID-19–Related Systemic Thrombosis? Courtney M. Campbell and Rami Kahwash Courtney M. CampbellCourtney M. Campbell Courtney M. Campbell, MD, PhD, Division of Cardiovascular Medicine, Davis Heart and Lung Research Institute, Suite 200, 473 W 12th Ave, Columbus, OH 43210. Email E-mail Address: [email protected] Division of Cardiovascular Medicine, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus. and Rami KahwashRami Kahwash Division of Cardiovascular Medicine, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus. Originally published9 Apr 2020https://doi.org/10.1161/CIRCULATIONAHA.120.047419Circulation. 2020;141:1739–1741Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: April 9, 2020: Ahead of Print SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is a novel coronavirus responsible for the current pandemic, resulting in an escalating number of cases and fatalities worldwide. Despite a high infection rate of coronavirus disease 2019 (COVID-19), only an estimated 15% of patients require hospitalization, with 5% requiring intensive care. Nearly half (49%) of patients requiring intensive care died. How and why patients succumb to SARS-CoV-2 infection is not well understood. A poignant New York Times article described the sudden decompensation and death of a young physician after she had documented viral clearance and was preparing to go home.Several early publications from the Wuhan region of China focused on describing clinical characteristics of hospitalized patients with severe COVID-19 illness. These initial observational studies demonstrate in severe cases evidence of coagulation dysfunction through elevated D-dimer, elevated lactate dehydrogenase, elevated total bilirubin, and decreased platelets with slight or no changes in partial thromboplastin time or activated partial thromboplastin time. In patients with severe or fatal COVD-19, there is also evidence of end-organ damage with acute kidney injury and primarily mildly elevated troponin. In the study by Shi et al,1 a significantly higher percentage of patients with cardiac injury (average troponin I 0.19 µg/L) died compared with those patients without cardiac injury (51.2% versus 4.5%, respectively).The mechanism of cardiac injury for COVID-19 is uncertain. No series of cardiac imaging data, such as echocardiography or cardiac magnetic resonance imaging, has been published for patients with COVID-19. Theories include direct viral damage via the angiotensin-converting enzyme 2 receptor, myocarditis, systemic inflammatory response with cytokine storm, destabilized coronary plaques, and aggravated hypoxia. In case reports of COVID-19–related myocarditis, patients had minimal pulmonary involvement and significant cardiac involvement and recovered from COVID-19. Cardiac biomarkers in the myocarditis cases were much higher than the average values of cardiac injury in patients with COVID-19 reported in the observational studies. Whether myocarditis as a COVID-19 mechanism applies broadly is uncertain. Excessive cytokine release has also been observed in patients with COVID-19. High cytokines were also found in patients with SARS-CoV and MERS-CoV (Middle East respiratory syndrome coronavirus), but subsequent studies demonstrated that corticosteroids did not improve mortality and delayed viral clearance. Tocilizumab, an interleukin-6 inhibitor, is being studied as a potential treatment option. However, elevated cytokines in this context could be a biomarker of critical illness with COVID-19 rather than the pathogenic mediator.In a joint webinar between the Chinese Cardiology Association and the American College of Cardiology on March 28, 2020, the Chinese cardiologists described diffuse microvascular thrombi in multiple organs on autopsy review of COVID-19 nonsurvivors. Given this diffuse thrombosis, Chinese physicians recommended treatment of patients with COVID-19 with systemic anticoagulation, but no trials or publications have evaluated this approach. Similar findings of diffuse multiorgan microvascular thrombosis without viral infiltrates were seen in an autopsy case report for a patient who died of SARS.2Thrombotic microangiopathy (TMA) can occur in many different clinical scenarios, including pathogenic complement activation. The complement system is a mediator of the innate immune response that promotes inflammation, defends against bacterial infections, and often neutralizes infectious viruses. In brief, the complement cascade can be activated via the classical pathway, triggered by antibody-antigen complexes; the alternative pathway, stimulated by specific surface antigens; and the lectin pathway, initiated by binding mannose residues on the pathogen surface. These pathways converge on the common pathway. The common pathway includes production of C3a and C5a inflammatory mediators and C3b-initiated pathogen opsonization and ends in formation of the C5b-9 membrane attack complex, which lyses target cells, resulting in cell death (Figure [A]). Two murine studies directly investigated complement activation in coronavirus infections and asked whether activation of the system would be protective or pathogenic. In a murine model lacking C3 and thus unable to activate the common complement pathway, SARS-CoV infection severity was decreased, with less respiratory dysfunction and lower cytokine levels despite equal viral loads (Figure [C]).2 The authors suggest that a significant portion of SARS-mediated disease is likely immune mediated. In a murine model of MERS-CoV infection, increased concentrations of C5a and C5b-9 were found in sera and lung tissues.4 Blocking C5a with a murine antibody alleviated lung and spleen damage, with decreased cytokine response and viral replication (Figure [D]).Download figureDownload PowerPointFigure. Coronavirus and complement.A, Simplified diagram of the common complement pathway. Eculizumab inhibits C5, preventing breakdown into C5a and C5b, which is an integral component of the membrane attack complex (MAC). B, In humans, overactivation of the complement pathway can lead to thrombotic microangiopathy, resulting in renal and cardiac dysfunction. In atypical hemolytic-uremic syndrome (aHUS), early treatment with eculizumab reverses organ dysfunction. C, On the basis of the mouse model of SARS-CoV (severe acute respiratory syndrome coronavirus)infection described by Gralinski et al,2 lack of the C3 protein results in improved lung function, less cytokine release, and no change in viral load compared with mice with an intact complement system. D, On the basis of the mouse model of MERS-CoV (Middle East respiratory syndrome coronavirus) infection described by Jiang et al,3 antibody blockade of C5 results in improved lung function, less cytokine release, and less viral load compared with untreated mice.In humans, excessive complement activation occurs in a number of pathological settings, leading to diffuse TMA and end-organ dysfunction (Figure [B]). Atypical hemolytic-uremic syndrome (aHUS) is a rare disorder of uncontrolled complement activation characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. TMA in aHUS results in renal dysfunction and, in rare cases, cardiac dysfunction.5 Patients often have an underlying genetic predisposition, with variants in the complement cascade. Alternatively, infection, pregnancy, and certain medications and autoimmune disorders can trigger complement-activating autoantibodies. Importantly, aHUS is treatable with a C5 complement inhibitor, eculizumab. If given early, eculizumab therapy can reverse both renal and cardiac dysfunction.5 Before the introduction of eculizumab, the prognosis of aHUS was poor, with 67% of adults dying within 5 years.Transplant-associated TMA is also thought to be initiated by excessive complement activation, trigged by endothelial injury from chemotherapy, radiation, or viral infection. A recent study showed that 78% of patients with transplant-associated TMA had a pathogenic or likely pathogenic variant in TMA and complement-associated genes.6 Importantly, endothelial injury is a hallmark of COVID-19. Like SARS-CoV, COVID-19 acts primarily through the angiotensin-converting enzyme 2 receptor, which is expressed widely in vascular tissues, including alveolar epithelium and cardiac pericytes.Complement inhibition may be a promising treatment for severe COVID-19 by reducing the innate immune-mediated consequences of severe coronavirus infection, and it would pair well with direct antiviral therapy. The published clinical observations of severe COVID-19 are consistent with excessive complement activation: elevated lactate dehydrogenase, D-dimer, and bilirubin; decreased platelets; mild anemia; renal and cardiac injury; and reportedly diffuse TMA. Patients with severe and fatal cases of COVID-19 might have increased susceptibility to TMA through a genetic predisposition to pathogenic complement activation. Complement inhibition was associated with favorable outcomes in SARS-CoV and MERS-CoV murine models and reversed cardiac dysfunction in aHUS-TMA, which mimics the pathological findings seen in COVID-19. Complement inhibition might be a new target in treating COVID-19–related systemic thrombosis. This approach is worthy of further investigation with a randomized, controlled clinical trial to investigate whether complement inhibition could improve the clinical course for COVID-19 patients with severe disease.DisclosuresNone.FootnotesThe opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.https://www.ahajournals.org/journal/circCourtney M. Campbell, MD, PhD, Division of Cardiovascular Medicine, Davis Heart and Lung Research Institute, Suite 200, 473 W 12th Ave, Columbus, OH 43210. Email [email protected]. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, Gong W, Liu X, Liang J, Zhao Q, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China [published online March 25, 2020].JAMA Cardiol. doi: 10.1001/jamacardio.2020.0950. https://jamanetwork.com/journals/jamacardiology/fullarticle/2763524.Google Scholar2. Xiang-Hua Y, Le-Min W, Ai-Bin L, Zhu G, Riquan L, Xu-You Z, Wei-Wei R, Ye-Nan W. Severe acute respiratory syndrome and venous thromboembolism in multiple organs.Am J Respir Crit Care Med. 2010; 182:436–437. doi: 10.1164/ajrccm.182.3.436CrossrefMedlineGoogle Scholar3. Gralinski LE, Sheahan TP, Morrison TE, Menachery VD, Jensen K, Leist SR, Whitmore A, Heise MT, Baric RS. Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis.mBio. 2018; 9:e01753-18. doi: 10.1128/mBio.01753-18CrossrefMedlineGoogle Scholar4. Jiang Y, Zhao G, Song N, Li P, Chen Y, Guo Y, Li J, Du L, Jiang S, Guo R, et al. Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV.Emerg Microbes Infect. 2018; 7:77. doi: 10.1038/s41426-018-0063-8CrossrefMedlineGoogle Scholar5. Campbell CM, Cassol C, Cataland SR, Kahwash R. Atypical haemolytic uraemic syndrome: a case report of a rare cause of reversible cardiomyopathy.Eur Heart J Case Rep. 2020; 4:1–6. doi: 10.1093/ehjcr/ytaa050CrossrefMedlineGoogle Scholar6. Gavriilaki E, Touloumenidou T, Sakellari I, Batsis I, Mallouri D, Psomopoulos F, Tsagiopoulou M, Koutra M, Yannaki E, Papalexandri A, et al. Pretransplant genetic susceptibility: clinical relevance in transplant-associated thrombotic microangiopathy.Thromb Haemost. March 4, 2020; 120:638–646. doi: 10.1055/s-0040-1702225CrossrefMedlineGoogle Scholar eLetters(0)eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetailsCited By Rhodes R, Love G, Da Silva Lameira F, Sadough Shahmirzadi M, Fox S and Vander Heide R (2024) Acute neutrophilic vasculitis (leukocytoclasia) in 36 COVID-19 autopsy brains, Diagnostic Pathology, 10.1186/s13000-024-01445-w, 19:1 Viderman D, Kotov A, Popov M and Abdildin Y (2024) Machine and deep learning methods for clinical outcome prediction based on physiological data of COVID-19 patients: a scoping review, International Journal of Medical Informatics, 10.1016/j.ijmedinf.2023.105308, 182, (105308), Online publication date: 1-Feb-2024. Kutlutürk I, Tokuç E, Karabaş L, Rückert R, Kaya M, Karagöz A and Munk M (2023) How the immune response to the structural proteins of SARS-CoV-2 affects the retinal vascular endothelial cells: an immune thrombotic and/or endotheliopathy process with in silico modeling, Immunologic Research, 10.1007/s12026-023-09412-1, 72:1, (50-71), Online publication date: 1-Feb-2024. Khokhlov R, Yarmonova M and Tribuntseva L (2024) Lesions of the heart and parenchymatous organs in patients with COVID-19 and other acute respiratory infections, Russian Family Doctor, 10.17816/RFD622794, 27:4, (21-32) Rizoli S, Peralta R, Al-Thani H, Ramzee A, El-Menyar A, Asim M, Shahid F, Fino A, Ata Y, El Baba H, Nair A and Al Maslamani M (2023) Descriptive Analysis of Thromboembolic Events in COVID-19 Patients in Qatar, Panamerican Journal of Trauma, Critical Care & Emergency Surgery, 10.5005/jp-journals-10030-1436, 12:3, (120-130), Online publication date: 30-Dec-2023. Sanda M (2023) Guest editorial: Organizational and management practices in COVID-19 business environments in Africa – interactive models, structures and strategies, African Journal of Economic and Management Studies, 10.1108/AJEMS-09-2023-576, 14:3, (333-338), Online publication date: 14-Nov-2023. Deri M, Ari Ragavan N, Niber A, Zaazie P, Akazire D, Anaba M and Andaara D (2023) COVID-19 shock in the hospitality industry: its effect on hotel operations within the Bono region of Ghana, African Journal of Economic and Management Studies, 10.1108/AJEMS-07-2022-0264, 14:3, (355-378), Online publication date: 14-Nov-2023. Kawakami E, Saiki N, Yoneyama Y, Moriya C, Maezawa M, Kawamura S, Kinebuchi A, Kono T, Funata M, Sakoda A, Kondo S, Ebihara T, Matsumoto H, Togami Y, Ogura H, Sugihara F, Okuzaki D, Kojima T, Deguchi S, Vallee S, McQuade S, Islam R, Natarajan M, Ishigaki H, Nakayama M, Nguyen C, Kitagawa Y, Wu Y, Mori K, Hishiki T, Takasaki T, Itoh Y, Takayama K, Nio Y and Takebe T (2023) Complement factor D targeting protects endotheliopathy in organoid and monkey models of COVID-19, Cell Stem Cell, 10.1016/j.stem.2023.09.001, 30:10, (1315-1330.e10), Online publication date: 1-Oct-2023. Tomo S, Kiran Kumar P, Yadav D, Sankanagoudar S, Charan J, Purohit A, Nag V, Bhatia P, Singh K, Dutt N, Garg M, Misra S, Sharma P and Purohit P (2023) Association of Serum Complement C3 Levels with Severity and Mortality in COVID 19, Indian Journal of Clinical Biochemistry, 10.1007/s12291-023-01148-x, 38:4, (447-456), Online publication date: 1-Oct-2023. Shama , Mahmood A, Mehmood S and Zhang W (2023) Pathological Effects of SARS-CoV-2 Associated with Hematological Abnormalities, Current Issues in Molecular Biology, 10.3390/cimb45090453, 45:9, (7161-7182) Ge X, Yu Z, Guo X, Li L, Ye L, Ye M, Yuan J, Zhu C, Hu W and Hou Y (2023) Complement and complement regulatory proteins are upregulated in lungs of COVID-19 patients, Pathology - Research and Practice, 10.1016/j.prp.2023.154519, 247, (154519), Online publication date: 1-Jul-2023. Safiriyu I, Fatuyi M, Mehta A, Naser A, Alexander E, Vovan H, Shamaki G and Bob-Manuel T (2023) Impact of COVID-19 Infection on the Clinical Outcomes of Pulmonary Embolism Hospitalizations : A Nationwide Analysis, Current Problems in Cardiology, 10.1016/j.cpcardiol.2023.101669, 48:7, (101669), Online publication date: 1-Jul-2023. Yusharyahya S, Japranata V, Jonlean R, Legiawati L and Astriningrum R (2023) Cutaneous manifestations in elderly patients with confirmed coronavirus disease 2019 and the disease outcomes: A systematic review, The Journal of Dermatology, 10.1111/1346-8138.16722, 50:5, (679-691), Online publication date: 1-May-2023. Purbey P, Roy K, Gupta S and Paul M (2023) Mechanistic insight into the protective and pathogenic immune-responses against SARS-CoV-2, Molecular Immunology, 10.1016/j.molimm.2023.03.009, 156, (111-126), Online publication date: 1-Apr-2023. Iwaniuk A and Jablonska E (2023) Neutrophils in Health and Disease: From Receptor Sensing to Inflammasome Activation, International Journal of Molecular Sciences, 10.3390/ijms24076340, 24:7, (6340) Mocanu A, Bogos R, Lazaruc T, Cianga A, Lupu V, Ioniuc I, Alecsa M, Lupu A, Ivanov A, Miron I and Starcea I (2023) Pitfalls of Thrombotic Microangiopathies in Children: Two Case Reports and Literature Review, Diagnostics, 10.3390/diagnostics13071228, 13:7, (1228) Zhao X, Wu H, Li S, Gao C, Wang J, Ge L, Song Z, Ni B and You Y (2023) The impact of the COVID-19 pandemic on SLE, Modern Rheumatology, 10.1093/mr/road030 Matošević M, Kos I, Davidović M, Ban M, Matković H, Jakopčić I, Vuković Brinar I, Szilágyi Á, Csuka D, Sinkovits G, Prohászka Z, Vrljičak K and Lamot L (2023) Hemolytic uremic syndrome in the setting of COVID-19 successfully treated with complement inhibition therapy: An instructive case report of a previously healthy toddler and review of literature, Frontiers in Pediatrics, 10.3389/fped.2023.1092860, 11 Marcos-Jubilar M, Lecumberri R and Páramo J (2023) Immunothrombosis: Molecular Aspects and New Therapeutic Perspectives, Journal of Clinical Medicine, 10.3390/jcm12041399, 12:4, (1399) Tang H, Qin S, Li Z, Gao W, Tang M and Dong X (2023) Early immune system alterations in patients with septic shock, Frontiers in Immunology, 10.3389/fimmu.2023.1126874, 14 Schmitz L, Pirotte M, Lebeau A, Ernst M, Fillet M, Devey A, Schmitt J, Cobraiville G, Binsfeld M, Gofflot S, Beguin Y and G (2023) of in patients: of and Therapeutic in Online publication date: M and A (2023) Hemolytic V, S, Silva A, R, S, Silva T, P, C, R, A, S and L outcomes of COVID-19 patients from a of The of and Online publication date: V, Z, Shahid Z, A, M, S, M, S, M, S, R and G Guidelines for Coronavirus Management in Cell and and Online publication date: and L An on angiotensin-converting enzyme 2 and in the of coronavirus disease for vascular and coagulation disease associated with severe acute respiratory syndrome coronavirus infection, Frontiers in S, G, G, S, M, E, M and S Previous the of Coronavirus Medical Online publication date: H, M, M, A, M, M, M, S, A and Y and of in Patients with Severe COVID-19 and the Association between the of and The Journal of Critical Care Medicine, Online publication date: Online publication date: A, S, A, M, K, N, E, D, I, G, M, M, S, D, A, P, M, M, S, S, M, F, M, R, P, A, R, El K, R, J, J, A, M, M, F, M, A, A, B, S, A, S, A, D, J, R, J, C, M, Wu H, J, D, A, M, V, A, Gupta G, A, P, C, P, N, X, M, J, M, M, M, G, K, F, Z, S, L, Du R, M, D, R, M, Nguyen T, N, J, J, H, M, N, R, S, A, A and P International controlled study of and outcomes , Journal of Online publication date: Ye J, Yang P, Yang Y and S Complement as a and and Frontiers in Immunology, P, S, M, P and M in COVID-19 – A review of the potential of to disease Molecular Immunology, Online publication date: N, Y, Kumar M, M and L of COVID in A Case in Patients a Indian Journal of and & Surgery, Online publication date: Roy B and S SARS-CoV-2 infection and mechanism of organ Journal of V, Mehta S, S, S and P COVID-19 Effects in and Online publication date: P, F, C, T, C, A, R, B, G, H, J, D, S and B of cardiac evidence for a disease in an autopsy Online publication date: I, A, I, N, and S of of the SARS-CoV-2 A B D and current of the and of and A review, Clinical and Online publication date: N, E, M, P, S, R, A and D Complement A approach in the against in Medical Online publication date: Gavriilaki E, S, Touloumenidou T, E, P, E, E, I, E, E, E, P, C, S, Papalexandri A, M, A, D, E, Sakellari I, A and A of Patients a Complement COVID-19 Current Issues in Molecular Biology, P, A, A, M, K, N, E, I, G, M, M, S, D, A, P, M, M, S, S, M, F, M, D, R, P, A, R, El K, R, B, J, J, A, M, M, F, M, A, A, B, S, A, S, A, D, M, Wu H, J, D, A, M, V, A, Gupta G, A, P, C, P, N, X, M, J, M, M, M, G, K, F, Z, S, L, M, Nguyen T, P, A, J, K, J, H, M, N, R, S and A of a COVID-19 A International Online publication date: M, G, R and A COVID-19 and Online publication date: N, M, K, I, M, A, N, L, L, W, S, H, M, C, D, A and L Complement system component is a of COVID-19 a and of patients to the for COVID-19 Journal of and Online publication date: D, L, A, I, T, A, K, D, V, E, D and SARS-CoV-2 and a with A Review, K, T, A, N, E, G, E, T, S, L, T, T, S, A, T, M and M Modern to the Management of with Atypical Hemolytic B, B, K, M, R, M, M and K How the of the to Systemic Pathology in and for Frontiers in Immunology, P, V, and J of of COVID-19 of the pandemic in Molecular and Clinical Online publication date: Online publication date: Y, Zhao B, Li T, Yang Z, Li S and W of in patients with COVID-19 A systematic review and Research Online publication date: E and Therapeutic Current , M, , , and A SARS-CoV-2 and potential of review of literature, for K, T, Y and K as a of Coronavirus Disease: A of P, C, C, C, N, I, E, J, C, M, C, J, C, A and B in COVID-19 and and pulmonary The Journal of Practice, A,

Topics & Concepts